SA Drug Schedules

classic Classic list List threaded Threaded
1 message Options
Reply | Threaded
Open this post in threaded view
|

SA Drug Schedules

Avarim
Administrator
Schedule l
[Schedule 1 added by s. 36 of Act No. 65 of 1974, substituted by Government Notices No. R420 of 7 March, 1975, No. R.2244 of 28 November, 1975, No. R.575 of 2 April, 1976 and No. R. 2082 of 5 November, 1976, amended by Government Notices No. R.278 of 25 February, 1977, No. R.437 of 1 April 1977, No. R. 1194 of July, 1977, No. R.1674 of 18 August, 1978 (as amended by Government Notice No. R.2410 of 8 December, 1978), No. R.1926 of 31 August, 1979, No. R.2416 of 12 November, 1982 and No. R. 1289 of 14 June, 1985 (as amended by Government Notice No. 155 of 31 January, 1986), substituted by Government Notice No. 225 of 17 February, 1989 and amended by Government Notice No. R.2841 of 7 December, 1990.]
All substances referred to in this Schedule are excluded when specifically packaged, labelled and used for industrial and non-medicinal laboratory purposes.
All substances, preparations and mixtures referred to in this Schedule are also excluded when registered and sold in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947).
All substances referred to in this Schedule include the following:
( a)
The salts and esters of such substances, where the existence of such salts and esters is possible; and
( b)
all preparations and mixtures of such substances where such preparations and mixtures are not expressly excluded.
Acetanilide and alkyl acetanilides.
Acetyldihydrocodeine; preparations and mixtures containing 20 milligrams or less of acetyldihydrocodeine per recommended or prescribed dose. (S7)
Aconite alkaloids; substances, preparations and mixtures containing less than 0.02 per cent thereof (S2)
Adrenaline (epinephrine), except inhalants and except preparations for injection and except ophthalmic preparations when intended for glaucoma. (S2, S3, S4)
Amyl nitrite.
Anethole trithione.
Anticoagulants, when intended for application to the skin. (S4)
Antimalarials; preparations containing substances in the 4-aminoquinoline, 8-aminoquinoline, diguanide and diaminopyrimidine groups of compounds, when intended specifically for malaria prophylaxis. (S4)
Antimicrobial substances, namely bacitracin, gramicidin, polymyxin B and tyrothricin, when intended for application to the skin, nares and external ear, as excluded from the conditions of Schedule 4. (S2, S4)
Antimony potassium tartrate and antimony sodium tartrate; preparations and mixtures containing less than 1.0 per cent thereof. (S2)
Antipyrine (phenazone): preparations and mixtures, when intended for application to the skin. (S2)
Apomorphine: preparations and mixtures containing less than 0.2 per cent thereof. (S2)
Arsenic: substances, preparations and mixtures containing the equivalent of less than 0.01 pet cent of arsenic trioxide. (S2)
Atropine: substances, preparations and mixtures containing less than 0.1 per cent thereof, except ophthalmic preparations. (S2, S3)
Azelaic acid.
Barbituric acid and its derivatives, unless listed in another Schedule, excluding amobarbital, cyclobarbital, pentobarbital and secobarbital: preparations and mixtures containing 30 milligrams or less per minimum recommended or prescribed dose, when intended for continued use in asthma, and 90 milligrams or less phenobarbitone per minimum recommended or prescribed dose, when intended for continued use in epilepsy. (S2, S5, S6, S7)
Bee venom, when intended for application to the skin. (S4)
Belladonna alkaloids: substances, preparations and mixtures containing less Gum 0. 1 per cent thereof, and including belladonna plasters. (S2)
Benorylate.
Beta-aminopropylbenzene and beta-aminoisopropylbenzene as excluded from the conditions of Schedule 5. (S5)
Beta-carotene, when intended for medicinal purposes.
Bioallethrin.
Bitolterol.
Calabar bean alkaloids; substances, preparations and mixtures containing less than 0.2 per cent thereof. (S2)
Calcium salts; preparations thereof, when intended for injection.
Camylofin.
Cantharidin; substances, preparations and mixtures containing less than 0,01 per cent thereof. (S2)
Canthaxanthin, when intended for medicinal purposes.
Chloramine, when intended for human vaginal use.
Chlorodyne (Chloroform and Morphine Tincture BP 1980) or any preparation or mixture thereof described as chlorodyne; preparations and mixtures containing 5,0 per cent or less of chlorodyne in combination with other active medicinal ingredients. (S7)
Chloroform, except substances, preparations and mixtures containing less than 20 per cent of chloroform.
Clanobutin.
Clonidine when intended for treatment of migraine. (S3)
Codeine (methylmorphine): preparations and mixtures containing 20 milligrams or less of codeine per recommended or prescribed dose. (S7)
Contrast media.
Cresol and phenol; preparations and mixtures containing 3,0 per cent or more of either of these substances.
Dapsone and its derivatives, unless listed in another Schedule; preparations and mixtures intended specifically for malaria prophylaxis. (S4)
Dextromethorphan. (S7)
Dialysate preparations.
Diclophenac. when intended for application to the skin. (S3)
Dihydrocodeine: preparations and mixtures containing 20 milligrams or less of dihydrocodeine per recommended or prescribed dose. (S7)
Ephedra alkaloids (natural of synthetic); preparations and mixtures intended for application to the skin, eyes, ears and nares containing 1,0 per cent or less of ephedra alkaloids, and other preparations and mixtures containing not more than 30 milligrams of ephedrine or ephedra alkaloids per dose. (S2)
Escin (aescin); medicinal preparations and mixtures thereof intended for application to the skin and containing 1,0 per cent or less of escin. (S3)
Ethacridine.
Ether (diethyl ether); all substances, preparations and mixtures containing more than 20 per cent of ether.
Ethylmorphine; preparations and mixtures containing 20 milligrams or less of ethylmorphine per recommended or prescribed dose. (S7)
Ethylphenylephrine.
Etofenamate. when intended for application to the skin.
Fedrilate.
Fenbendazole.
Flufenamic acid. when intended for application to the skin. (S3)
Fluorescein, when intended for ophthalmic use.
Fluorides: oral medicinal preparations and mixtures thereof containing less than 0.25 milligrams of fluorine as fluoride per recommended daily dose. (S2)
Gadopentetic acid.
Gamma benzene hexachloride: human medicinal preparations and mixtures containing more than 1,0 per cent thereof, when intended for application to the skin.
Gelsemium alkaloids: substances, preparations and mixtures containing less than 0,1 per cent thereof. (S2)
Glycosaminoglycan polysulphate (previously mucopolysaccharide poly-sulphuric acid ester) when intended for application to the skin. (S4)
Homatropine; preparations and mixtures containing less than 0,1 per cent thereof, except ophthalmic preparations. (S2, S3)
Hormones (natural or synthetic), with either hormonal or anti-hormonal action, when intended for application to the skin or for human vaginal use. (S3. S4)
Halogenated hydroxyquinolines, when intended for application to the skin. (S4)
Hyoscine: substances, preparations and mixtures containing less than 0,1 per cent thereof, except transdermal preparations when intended for the prevention of the symptoms of motion sickness. (S2)
Indanazoline.
lndomethacin, when intended for application to the skin. (S3)
Injections. unless listed in another Schedule.
Iopromide.
Ipecacuanha alkaloids; substances, preparations and mixtures thereof containing more than 0,01 per cent and less than 0,2 per cent alkaloids, calculated as emetine. (Also see Schedule 4 under "emetine".)
Lactobacillus acidophilus and Lactobacillus bifidus, when intended for therapeutic purposes.
Lead acetate.
Lead plaster and its combinations.
Live attenuated measles virus.
Live attenuated rubella virus.
Lobelia alkaloids; substances, preparations and mixtures containing less than 0,5 pet cent thereof. (S2)
Local anaesthetics, except when intended for ophthalmic and for parenteral use. (S4)
Lodoxamide.
Lysozyme, when intended for application to the skin. (S4)
Macrogolethers, when intended for human vaginal use.
Mercuric ammonium chloride.
Mercuric chloride: substances. preparations and mixtures containing less than 1,0 per cent thereof. (S2)
Mercuric iodide.
Mercuric oxides: substances. preparations and mixtures thereof, except those containing less than 3,0 per cent of mercury.
Mercury. organic compounds: substances. preparations and mixtures intended for application to the skin and mucous membranes and containing less than the equivalent of 0,6 per cent of elemental mercury, except when in the form of aerosols. (S2)
Metacresol sulphonic acid formaldehyde, when intended for human vaginal use.
Methoxyphenamine.
Microfibrillar collagen hydrochloride.
Morphine; mixtures containing 0.2 per tent or less of morphine, calculated as anhydrous morphine. (S7)
N-acetyl-aspartyl-glutamic acid.
Naphazoline, when intended for nasal use.
Nicotinic acid; oral medicinal preparations and mixtures thereof containing more than 30 milligrams per recommended daily dose.
Nitrofurantoin, when intended for application to the skin. (S4)
Nitrofurazone, when intended for application to the skin. (S4)
Nitroscanate.
Norcodeine: preparations and mixtures containing 20 milligrams or less of norcodeine per recommended or prescribed dose. (S7)
Nux vomica: substances, preparations and mixtures containing less than 0.2 per cent of strychnine. (S2)
Opium; mixtures containing not more than 0.2 per cent of morphine, calculated as anhydrous morphine. (S7)
Ornidazole, when intended for application to the skin. (S4)
Oxibendazole.
Oxymetazoline. when intended for nasal use.
Pancreatic enzyme-containing preparations. unless listed in another Schedule.
Pancrelipase.
Papaverine: substances, preparations and mixtures containing less than 0.2 pet cent thereof. (S2)
Phenylbutazone and its derivatives, when intended for application to the skin, unless listed in another Schedule. (S4)
Phenylephrine. except ophthalmic preparations containing 0.2 per cent or less of phenylephrine.
Pholcodine: preparations and mixtures containing 20 milligrams or less of pholcodine per recommended or prescribed dose. (S7)
Pholedrine.
Phospholipids. when applied for therapeutic purposes.
Piperonyl butoxide.
Potassium chloride. when intended for intravenous infusion or for injection. (S2)
Potassium dichromate.
Proguanil.
Propylhexedrine. when used as a vasoconstrictor and decongestant in nose preparations and inhalants. (S4)
Proteolytic (fibrinolytic) enzymes for oral use and when intended for application to the skin, unless listed in another Schedule. and except when intended for injection and except when intended for soft contact lens cleaners. (S4)
Pyridoxilate.
Quinine; preparations and mixtures containing more than 1,0 per cent thereof.
Radix valerianae and its extracts; preparations and mixtures containing more than 10 per cent thereof.
Sabadilla alkaloids; substances, preparations and mixtures containing less than 1,0 per cent thereof. (S2)
Sodium cromoglycate.
Sodium pentosan polysulphate.
Solcoseryl; preparations thereof intended for application to the skin, to the mucous membranes of the mouth and to the lips. (S3, S4)
Strychnine; preparations and mixtures containing less than 0,2 per cent thereof, except the substance. (S2, S4)
Sulphonamides, when intended for application to the eyes, nares and vagina. (S4)
Tetrahydrozoline, when intended for nasal use.
Theophylline and its derivatives, unless listed in another Schedule, except preparations for injection and except inhalants. (S2, S4)
Ticlatone.
Tolmetin, when intended for application to the skin. (S3)
L-tryptophan when intended for medicinal use as supplementation for nutritional purposes. (S5)
Xylometazoline, when intended for nasal use.
Schedule 2
[Schedule 2 added by s. 36 of Act No. 65 of 1974, substituted by Government Notices No. R.420 of 7 March, 1975, No. R.2244 of 28 November, 1975, No. R.575 of 2 April, 1976 and No. R.2082 of 5 November, 1976, mended by Government Notices No. R.278 of 25 February, 1977, No. R.437 of 1 April, 1977, No. R.1988 of 30 September, 1977, No. R. 1674 of 18 August, 1978 (as amended by Government Notice No. R.2410 of 8 December, 1978), No. R.1926 of 31 August, 1979, No. R.2507 of 9 November, 1979, No. R.2416 of 12 November, 1982, No. R.1289 of 14 June, 1985 (as amended by Government Notice No. 155 of 31 January, 1986) and No. 154 of 31 January, 1986, substituted by Government Notice No. 225 of 17 February, 1989 and amended by Government Notices No. R.1132 of 2 June, 1989, No. R.1862 of 10 August, 1990 and No. R.2841 of 7 December, 1990.]
All substances referred to in this Schedule are excluded when specifically packaged, labelled and used for industrial and non-medicinal laboratory purposes.
All substances, preparations and mixtures referred to in this Schedule are also excluded when registered and sold in terms of the provisions of the Fertilizers, Farm Feeds Agricultural Remedies and Stock Remedies Act. 1947 (Act 36 of 1947).
All substances referred to in this Schedule include the following:
( a)
The salts and esters of such substances, where the existence of such salts and esters is possible; and
( b)
all preparations and mixtures of such substances, where such preparations and mixtures are not expressly excluded.
Acetarsol, when intended for human vaginal use.
Acetylcysteine.
Aconite alkaloids; substances, preparations and mixtures containing 0,02 per cent or more thereof. (S1)
Acrivastine.
Adrenaline (epinephrine), when intended for inhalation. (S1, S3, S4)
Alkaloids and glycosides: all poisonous alkaloids and glycosides. and the salts of such poisonous alkaloids and glycosides not specifically named in any other Schedule.
Aminopentamide.
Amobarbital, cyclobarbital and pentobarbital; preparations and mixtures thereof containing 30 milligrams or less per minimum recommended or prescribed dose, when intended for continued use in asthma, and 50 milligrams or less per minimum recommended or prescribed dose, when intended for continued use in epilepsy. (S1, S5. S6)
Antihistaminics, irrespective of indication or dosage form, unless listed in another Schedule. (S5)
Antimicrobial substances, namely clotrimazole. mupirocin, natamycin and nystatin, when intended for application to the skin. nares and external ear, as excluded from the conditions of Schedule 4. (S1, S4)
Antimony potassium tartrate and antimony sodium tartrate; substances, preparations and mixtures containing 1,0 per cent or more thereof. (S1)
Antipyrine (phenazone), except preparations and mixtures, when intended for application to the skin. (S1)
Apomorphine; preparations and mixtures containing 0,2 per cent or more thereof. (S1)
Aptocaine.
Arecoline.
Arsenic; substances, preparations and mixtures containing the equivalent of 0,01 per cent or more of arsenic trioxide. (S1)
AS XVII" ("Spasmo-Urgenin").
Atropine, substances, preparations and mixtures containing 0,1 per cent or more thereof except ophthalmic preparations. (S1,S3)
Belladonna alkaloids; substances. preparations and mixtures containing 0,1 per cent or more thereof, excluding belladonna plasters. (S1)
Benproperine.
Benzethonium chloride, when intended for human vaginal use.
Bifonazole. when intended for application to the skin.
Biologicals, when intended for human use.
Bismuth, when intended for oral use.
Bovonium metilsulphate.
Bromhexine.
Bromides; preparations and mixtures thereof containing less than 80 milligrams of bromine as bromide per recommended daily dose. (S5)
Bufexamac, when intended for application to the skin.
Butinoline.
Calabar bean alkaloids; substances, preparations and mixtures containing 0,2 per cent or more thereof. (S1)
Calcium dobesilate.
Camphorated Opium Tincture BP.
Cantharidin; substances, preparations and mixtures containing 0,01 per cent or more thereof. (S1)
Carbocisteine.
Carbuterol, except when contained in respirator solutions (S3) and except when intended for injection. (S4)
Carisoprodol.
Chlorhexidine. when intended for human vaginal use.
Chlormezanone: mixtures thereof where the maximum recommended or prescribed dose does not exceed 100 milligrams of chlormezanone. (S5)
Chlorprenaline.
Chlorzoxazone.
Cyclandelate.
Cylopentolate, except ophthalmic preparations thereof. (S3)
Dicyclomine.
Difenoxin (or diphenoxylic acid); mixtures containing, per dosage unit, 0,5 milligrams or less of difenoxin. calculated as the base, and a quantity of atropine sulphate equal to at least 5,0 per cent of such quantity of difenoxin, calculated as the base. as is present in the mixture. (S7)
Diosmine.
Diphenoxylate: preparations containing not more than 2.5 milligrams of diphenoxylate. calculated as the base. and not less than 25 micrograms of atropine sulphate per dosage unit. (S7)
Dithiazanine.
D-norpseudoephedrine.
Domperidone.
Econazole. when intended for application to the skin. (S4)
Emepronium.
Ephedra alkaloids (natural or synthetic), except preparations and mixtures intended for application to the skin, eyes, ears and nares and containing 1,0 per cent or less of ephedra alkaloids, and other preparations and mixtures containing 30 milligrams or less of ephedrine or ephedra alkaloids per dose. (S1)
Ergot alkaloids (natural or synthetic), when intended for the treatment of migrant. (S4)
Exalamide.
Felbinac, when intended for application to the skin
Fenoterol, except when contained in respirator solutions (S3) and except when intended for injection or for the prevention or delay of labour. (S4)
Fenticonazole, when intended for application to the skin.
Flavoxate.
Flucytosine, when intended for application to the skin. (S4)
Fluorides; oral medicinal preparations and mixtures thereof containing 0,25 milligrams or more of fluorine as fluoride per recommended daily dose. (S1)
Furazolidone, except preparations thereof intended for addition to animal feeds. (S4)
Gelsemium alkaloids; substances, preparations and mixtures containing 0,1 per cent or more thereof. (S1)
Glycopyrronium.
Hexametazime.
Hexoprenaline, except when contained in respirator solutions (S3) and except when intended for injection or for the prevention or delay of labour. (S4)
Homatropine; preparations and mixtures containing 0,1 per cent or more thereof, except ophthalmic preparations. (S1, S3)
Hydrocortisone and hydrocortisone acetate when used as a single active ingredient in a maximum concentration of 0,5 per cent in preparations intended for application to the skin. (S4)
Hydroquinone; preparations and mixtures containing 2 per cent or less thereof, when intended for application to the skin. (S3)
Hyoscine; substances, preparations and mixtures containing 0,1 per cent or more thereof, and transdermal preparations when intended for the prevention of the symptoms of motion sickness. (S1)
Ibuprofen, when used in oral medicinal preparations as single active ingredient where the recommended daily dose for adults does not exceed 1,2 grams and that for children up to and including the age of 12 years does not exceed 20 milligrams per kilogram of body weight, except when intended for treatment of inflammatory, joint diseases. (S3)
Idoxuridine, when intended for application to the skin. (S4)
lmidazole, when intended for application to the skin.
Insulin. in cases of emergency. (S3)
Ipratropium bromide.
Isoaminile.
Isoconazole, when intended for application to the skin. (S4)
Isoprenaline (isoproterenol). except when contained in respirator solutions (S3) and except when intended for injection. (S4)
Isopropamide.
Isosorbide, in cases of emergency. (S3)
Ketoconazole, when intended for application to the skin. (S4)
Ketotifen.
Lobelia alkaloids; substances. preparations and mixtures containing 0,5 per cent or more thereof. (S1)
Loperamide.
Loratadine.
Malathion.
Mebendazole.
Mebevenne.
Meperueolate bromide.
Mephenesin
Mercuric chloride; substances, preparations and mixtures containing 1,0 per cent or more thereof. (S1)
Mercury organic compounds: substances. preparations and mixtures containing the equivalent of 0,6 per cent or more of elemental mercury. or substances. preparations and mixtures in the form of aerosols, intended for application to the skin and mucous membranes. (S1)
Mesna.
Metaproterenol (orciprenaline), except when contained in respirator solutions (S3) and except when intended for injection or for the prevention or delay of labour. (S4)
Methenamine (hexamine), except when intended for application to the skin.
Methixene.
Methocarbamol.
Miconazole, when intended for application to the skin. (S4)
Nitroglycerine, when intended for medicinal use in cases of emergency. (S3)
Nux vomica; substances, preparations and mixtures containing 0,2 per cent or more of strychnine. (S1)
Octatropine methylbromide.
Oleoresin of aspidium (Filix Mas).
Orphenadrine.
Orthodichlorobenzene, when intended for human medicinal use.
Oxyphencyclimine.
Oxyphenonium.
Papaverine; substances, preparations and mixtures containing 0,2 per cent or more thereof. (S1)
Paradichlorobenzene, when intended for human medicinal use.
Pentaerythritol tetranitrate, in cases of emergency. (S3)
Pentoxifylline.
Phenazopyridine.
Phenylpropanolamine.
Pinaverium.
Pipenzolate.
Pipoxolan.
Pirbuterol, except when contained in respirator solutions. (S3)
Pizotifen; preparations and mixtures, when intended for prophylaxis of migraine. (S5)
Podophyllum resin; preparations and mixtures containing 20 per cent or less thereof. (S4)
Poldine methylsulphate.
Potassium chloride, where the recommended dose is more than 20 millimol of potassium (1 500 milligrams of potassium chloride) per 24 hours, except when intended for intravenous infusion or for injection (S1) and except when contained in oral rehydration preparations.
Povidone iodine, when intended for human vaginal use.
Prifinium bromide.
Procaterol, except when contained in respirator solutions. (S3)
Procyclidine.
Proglumide.
Propantheline bromide.
Propentofylline, when intended for veterinary use.
Propyphenazone.
Pyrodifenium.
Reproterol, except when contained in respirator solutions. (S3)
Rimiterol, except when contained in respirator solutions (S3) and except when intended for injection. (S4)
Sabadilla alkaloids; substances, preparations and mixtures containing 1,0 per cent or more thereof. (S1)
Salbutamol, except when contained in respirator solutions (S3) and except when intended for injection. (S4)
Salmefamol, except when contained in respirator solutions (S3) and except when intended for injection. (S4)
Siccanin, when intended for application to the skin.
Strychnine; preparations and mixtures containing 0,2 per cent or more thereof, except the substance. (S1. S4)
Terbutaline, except when contained in respirator solutions. (S3).
Theophylline, when intended for inhalation. (S1. S4)
Thiabendazole, when intended for application to the skin (S4)
Timepidium.
Tioconazole, when intended for application to the skin (S4).
Trimebutine.
Tulobuterol, except when contained in respirator solutions. (S3)
Schedule 3
[Schedule 3 added by s. 36 of Act No. 65 of 1974, substituted by Government Notices No. R.420 of 7 March, 1975, No. R.2244 of 28 November, 1975, No. R.575 of 2 April, 1976 and No. R.2082 of 5 November, 1976, amended by Government Notices No. R.278 of 25 February, 1977, No. R.437 of 1 April, 1977, No. R. 1674 of 18 August, 1978 (as amended by Government Notice No. R.2410 of 8 December, 1978), No. R. 1926 of 31 August, 1979. No. R.2507 of 9 November, 1979, No. R.658 of 27 March, 1981, No. R. 1289 of 14 June, 1985 and No. 154 of 31 January, 1986, substituted by Government Notice No. 225 of 17 February, 1989 and amended by Government Notice No. R.2841 of 7 December, 1990.]
All substances referred to in this Schedule are excluded when specifically packaged, labelled and used for industrial and non-medicinal laboratory purposes.
All substances, preparations and mixtures referred to in this Schedule are also excluded when registered and sold in terms of the provisions of the Fertilizers. Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947).
All substances referred to in this Schedule include the following:
( a)
The salts and esters of such substances, where the existence of such salts and esters is possible; and
( b)
all preparations and mixtures of such substances, where such preparations and mixtures are not expressly excluded.
Acebutolol.
Acetazolamide.
Acetohexamide.
Acetylcholine, when intended for ophthalmic use.
Acipimox.
Adrenaline (epinephrine): ophthalmic preparations thereof, when intended for glaucoma. (S1, S2, S4)
Alclofenac.
Allopurinol.
Alprenolol.
Amiloride.
5-aminosalicylic acid.
Ancrod.
Anthiolimine, when intended for injection.
Arsanilic acid.
Atenolol.
Atropine: ophthalmic preparations thereof. (S1. S2)
Azapropazone.
Beclamide.
Benfluorex.
Benoxaprofen.
Benzbromarone.
Benzydamine.
Bepridil.
Beta-benzalbutyramide.
Beta-galactosidase, when intended for therapeutic purposes.
Betahistine.
Betaxolol.
Bethanidine.
Bevantolol.
Bezafibrate.
Bisoprolol.
Bopindolol.
Buflomedil.
Buformin.
Bumetanide.
Cadralazine.
Calcium carbimide.
Calcium disodium edetate, when intended for injection.
Carazolol.
Carbachol; ophthalmic preparations thereof when intended for glaucoma. (S4)
Carbamazepine.
Carbenoxolone, except when intended for application to the oral mucosa.
Carbuterol, when contained in respirator solutions. (S2, S4)
Carprofen.
Carteolol.
Carvedilol.
Chenodeoxycholic acid.
Chlorazanil.
Chlorexolone.
Chlorothiazide and other derivatives of benzo- 1,2,4-thiadiazine-7-sulphonamide-1, l-dioxide, whether hydrogenated or not, including hydrochlorothiazide, bendrofluazide, benzthiazide, cyclopenthiazide, hydro flumethiazide, metchlorothiazide and polythiazide.
Chlorpropamide.
Chlorthalidone.
Cholestipol.
Chromonar.
Clofibrate.
Clonidine, except when intended for the treatment of migraine. (S1)
Colchicine.
Copper salts, when intended for injection for veterinary use.
Cyclopentolate: ophthalmic preparations thereof. (S2)
Debrisoquine.
Dichlorphenamide.
Diclophenac, except when intended for application to the skin. (S1)
Diflunisal.
Diftalone.
Dihydroergocristine.
Digitalis; its glycosides and other active principles thereof, unless diluted below one unit (BP) in each 2.0 grams.
Dilevalol.
Diltiazem.
Dimercaprol, when intended for injection.
Dipivefrin.
Dipyridamole.
Dipyrocetyl.
Dithranol.
Doxazosin.
Endralazine.
Escin (aescin), except preparations and mixtures thereof intended for application to the skin and containing 1.0 per cent or less of escin. (S1)
Esculin, when intended for oral use.
Esmolol.
Ethacrynic acid.
Ethambutol.
Ethionamide, when intended for oral use.
Ethosuximide.
Etisazol.
Etodolac.
Etodolic acid.
Fenbufen.
Fenclofenac.
Fendiline.
Fenofibrate.
Fenoprofen.
Fenoterol, when contained in respirator solutions. (S2, S4)
Fentiazac.
Floctafenine.
Flufenamic acid, except preparations and mixtures intended for application to the skin. (S1)
Flunixim meglumine.
Flurbiprofen, except when intended for ophthalmic use. (S4)
Furosemide.
Gamma globulin, when intended for injection.
Gemfibrozil.
Glafenine.
Glibenclamide.
Glibornuride.
Glicazide.
Glimidine.
Glipizide.
Guanabenz.
Guanethidine.
Guanfacine.
Guanoxan.
Hexoprenaline, when contained in respirator solutions. (S2, S4)
Homatropine; ophthalmic preparations thereof. (S1, S2)
Hormones (natural or synthetic), when intended for oral contraception. (S1, S4)
Hydralazine.
Hydroquinone: preparations and mixtures thereof containing more than 2,0 per cent hydroquinone. (S2)
Ibuprofen, when specifically intended for the treatment of inflammatory joint diseases. (S2)
Indapamide.
Indomethacin, except when intended for application to the skin. (S1)
Indoprofen.
Indoramin.
Insulin, except in cases of emergency. (S2)
Iron salts, when intended for injection.
Isoniazid and its derivatives, unless listed in another Schedule.
Isoprenaline (isoproterenol), when contained in respirator solutions. (S2, S4)
Isosorbide, except in cases of emergency. (S2)
Isoxicam.
Isradipine.
Ivermectin.
Ketanserin.
Ketoprofen.
Labetalol.
Levobunolol.
Lidoflazine.
Lonazolac.
Meclofenamic acid.
Mefenamic acid.
Mepindolol.
Mesulphene.
Metaproterenol (orciprenaline), when contained in respirator solutions. (S2, S4)
Metformin.
Methimazole.
Methsuximide.
Methyldopa and its esters.
Metipranolol.
Metolazone.
Metoprolol.
Nabumetone.
Nadolol.
Naftidrofuryl.
Naproxen.
Nicardipine.
Nicotine, when intended for human medicinal use.
Nifedipine.
Niflumic acid.
Nimodipine.
Nitrendipine.
Nitroglycerine, when intended for medicinal use, except in cases of emergency. (S2)
Oxaprozin.
Oxcarbazepine.
Oxiracetam.
Oxovinca.
Oxprenolol.
Oxybutynin.
Para-aminosalicylic acid and its esters.
Penbutolol.
Penicillinase, when intended for injection.
Pentaerythritol tetranitrate, except in cases of emergency. (S2)
Pentolinium.
Phenformin.
Phenoxymethylpenicillin, when intended for the prophylaxis of rheumatic fever. (S4)
Phentolamine.
Phenytoin.
Physostigmine; ophthalmic preparations thereof. when intended for glaucoma. (S4)
Pilocarpine; ophthalmic preparations thereof intended for glaucoma. (S4)
Pindolol.
Piracetam.
Pirbuterol, when contained in respirator solutions. (S2)
Piretanide.
Piroxicam.
Pirprofen.
Potassium canrenoate.
Practolol.
Pralidoxime, when intended for injection.
Prazosin.
Primidone.
Probcnecid.
Probucol.
Procaterol, when contained in respirator solutions. (S2)
Proctofene.
Propranolol.
Proquazone.
Proscillaridine.
Prothionamide, when intended for oral use.
Pyguem africanum (lipido-sterolic complex extract thereof).
Pyrazinamide, when intended for oral use.
Pyrithioxin.
Raubasine.
Rauwolfia alkaloids.
Reproterol, when contained in respirator solutions. (S2)
Reserpine (natural or synthetic).
Rimiterol, when contained in respirator solutions. (S2, S4)
Roxarzone (3-nitro-4-hydroxyphenylarsonic acid), when intended for veterinary use.
Salbutamol when contained in respirator solutions. (S2, S4)
Salmefamol, when contained in respirator solutions. (S2, S4)
Solcoseryl; ophthalmic preparations thereof. (S1, S4)
Sotalol
Spironolactone.
Strophanthus; its glycosides and their hydrolysis products, and their derivatives, unless listed in another Schedule.
Sulindac.
Suloctidil
Sulphinpyrazone.
Sulthiame.
Suprofen.
Sylimarin.
Tenoxicam.
Terazosin.
Terbutaline, when contained in respirator solutions. (S2)
Terizidone.
Terodiline.
Thiacetazone.
Thyroid gland and its active principles and derivatives, unless listed in another Schedule.
Tiaprofenic acid.
Timolol.
Tolamolol.
Tolazamide.
Tolbutamide.
Tolfenamic acid.
Tolmetin, except when intended for application to the skin. (S1)
Tretinoin.
Triamterene.
Tricaine.
Trimethadione.
Tropicamide.
Tulobuterol, when contained in respirator solutions. (S2)
Ursodeoxycholic acid.
Valproic acid and its derivatives, unless listed in another Schedule.
Verapamil (iproveratril).
Veratrum alkaloids.
Vincamine.
Vinpocetine.
Vitamin A; preparations thereof for injection and oral preparations and mixtures thereof containing more than l0 000 I.U. per recommended daily dose.
Vitamin D; preparations thereof for injection and oral preparations and mixtures thereof containing more than 500 I.U. per recommended daily dose.
Xamoterol
Xipamide.
Zinc salts for oral ingestion where the daily dose is more than 50 milligrams of elemental zinc.
Zomepirac.
Schedule 4
[Schedule 4 added by s. 36 of Act No. 65 of 1974, substituted by Government Notices No. R.420 of 7 March, 1975, No.R.2244 of 28 November, 1975, No. R.575 of 2 April, 1976 and No. R.2082 of 5 November, 1976, amended by Government Notices No. R.279 of 25 February, 1977, No. R.437 of l April, 1977, No. R. 1194 of 1 July, 1977, No. R. 1674 of 18 August, 1978 (as amended by Government Notice No. R.2410 of 8 December, 1978), No. R. 1926 of 31 August, 1979, No. R.658 of 27 March, 1981, No. R.2416 of 12 November, 1982, No. R. 1289 of 14 June, 1985 and No. 154 of 31 January, 1986, substituted by Government Notice No. 225 of 17 February, 1989 and amended by Government Notice No. R.2841 of 7 December, 1990.].
All substances referred to in this Schedule ate excluded when specifically packaged, labelled and used for industrial and non-medicinal laboratory purposes.
All substances, preparations and mixtures referred to in this Schedule are also excluded when registered and sold in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947).
All substances referred to in this Schedule include the following:
( a)
The sails and esters of such substances where the existence of such salts and esters is possible; and
( b)
all preparations and mixtures of such substances, where such preparations and mixtures are not expressly excluded.
Acetarsone diethylamine salt, when intended for injection.
Acyclovir.
Adrenaline, when intended for injection. (S1, S2, S3)
Albendazole.
Alcuronium.
Alignpride.
Almitrine.
Aiphacalcidol.
Alpha-chymotrypsin, when intended for ophthalmic use.
Alpha-2-interferon.
Alpha-2b-interferon.
Alprostadil.
Amantadine.
Aminoglutethimide.
Aminopyrine (amidopyrine).
Amiodarone.
Amiphenazole.
Amrinone.
Amsacrine.
Anticoagulants, except preparations intended for application to the skin. (S1)
Antihemophilic factor.
Antimalarials, excluding the 4-aminoquinoline, 8-aminoquinoline, diguanide and diaminopyrimidine groups of compounds and preparations thereof, when these are intended specifically for malaria prophylaxis. (S1)
Antimicrobial substances (chemotherapeutic substances) synthesised in nature or the laboratory. being substances used in the specific treatment of infections, except the following when intended for topical application to the epidermis, nares and external ear.
Bacitracin; (S1)
clotrimazole; (S2)
gramicidin; (S1)
mupirocin; (S2)
natamycin; (S2)
nystatin; (S2)
polymixin B; (S1)
tyrothricin: (S1)
and except when intended for use as germicides and antiseptics, and except phenoxymethylpenicillin when intended for thc prophylaxis of rheumatic fever. (S3)
Antisera for veterinary, use.
Apraclonidine.
Aprotinin.
Arabinosylcytosine.
Arsenamide, when intended for injection.
L-Asparaginase.
Atracurium besilate.
Auranofin.
Azathioprine.
Baclofen.
Bee venom, except preparations intended for application to the skin. (S1)
Bemelgride.
Benazepril
Bethanechol
Biperiden.
Bleomycin.
Bretylium tosylate.
Bromocriptine
Bufenoide.
Bumadizone.
Buserelin.
Busulphan.
Calcitonin.
Calciriol.
Calcium polystyrene sulphorate, when intended for therapeutic purposes.
Caplopril.
Carbachol, except ophthalmic preparations thereof, when intended for glaucoma (S3)
Carbidopa.
Carboplatin.
Carbuterol, when intended for injection (S2).
Carmustine.
Ceruletide.
Chlorambucil.
Chlordantoin, when intended for human vaginal use.
Chloroquine, when intended for antirheumatic use (S1).
Cholestyramine resin.
Chymopapain, when intended for injection.
Cimetidine.
Cisapride.
Cisplatin.
Clofazimine.
Clomiphene.
Corticosteroids (natural or synthetic), except hydrocortisone and hydrocortisone acetate, when used as a single active ingredient in a maximum concentration of 0.5 per cent in preparations intended for application to the skin. (S2)
Cotetroxazine
Co-trimoxazole.
Cyclofenil.
Cyclophosphamide and its derivatives, unless listed in another Schedule.
Cyclosporin.
Cyproterone acetate.
Cytarabine.
Dacarbazine.
Dactinomycin (actinomycin D).
Dantrolene.
Dapsone and its derivatives. unless listed in another Schedule, except preparations and mixtures intended specifically for malaria prophylaxis. (S1)
Daunomycin (daunorubicin).
Demecarium.
Diazoxide.
Dictazuril.
Diclodronic acid.
Diethylcarbamazine.
Dihydralazine.
Dihydrotachysterol.
Di-isopropyl fluorophosphate.
Dilazep.
Diloxanide furoate.
Dimethyl sulphoxide.
Dinitrophenol.
Dinoprostone.
Diphemethoxidine.
Diphenidol.
Diprenorphine.
Disodium pamidronate.
Disopyramide.
Distigmine.
Disulfiram.
Ditazol.
Dobutamine.
Dopa.
Dopamine.
Doxapram.
Doxorubicin.
Econazole, except preparations and mixtures when intended for application to the skin (S2).
Edrophonium.
Emetine. except substances. preparations and mixtures containing less than 0.2 per cent of alkaloids. calculated as emetine.
Enalapril.
Encainide.
Enoxacin.
4-epidoxorubicin.
Ergot alkaloids (natural or synthetic). except preparations and mixtures thereof when intended for the treatment of migraine. (S-2)
Estramustine.
Etidronate.
Ethoglucid.
Etofamide.
Etoposide.
Famotidine.
Fazadinium.
Fenchlorphos.
Fenoterol, when intended for the prevention or delay of labour and preparations thereof for injection. (S2)
Fertirelin.
Flecainide.
Fluconazole.
Flucytosine, except preparations and mixtures intended for application to the skin. (S2)
Flugestone.
Flunisolide.
5-fluorouracil.
Flurbiprofen, when intended for ophthalmic use. (S3)
Flutamide.
Fosinopril.
Ftorafur.
Furazolidone, when intended for addition to animal feeds (S2)
Gallamine.
Gestrinone.
Glycosaminoglycan polysulphate (previously mucopolysaccharide poly-sulphuric acid ester), except when intended for application to the skin. (S1)
Goserelin.
Halofantrine
Halofenate.
Halogenated hydroxyquinolines, except, when intended for application to the skin. (S1).
Hepuminol.
Hexoprenaline, when intended for the prevention or delay of labour and preparations thereof for injection. (S2)
Hormones (natural or synthetic), with either hormonal or antihormonal action, except when intended for application to the skin, when intended for human vaginal use and when intended for oral contraception, and excluding insulin and epinephrine (adrenaline). (S1, S2, S3)
Hyaluronic acid-B.
Hycanthone.
Hydroxyurea.
Idoxuridine, except when intended for application to the skin. (S2)
Inosiplex (inosine pranabex).
Intra-uterine devices.
Isoconazole, except when intended for application to the skin. (S2)
Isopirin.
Isoprenaline (isoproterenol), when intended for injection. (S2)
Itraconazole.
Ketoconazole, except when intended for application to the skin. (S2)
Levallorphan.
Levamisole.
Lisinopril.
Local anaesthetics, when intended for ophthalmic and parenteral use. (S1)
Lomustine.
Lysozyme, except preparations and mixtures when intended for application to the skin. (S1)
Mecamylamine.
Melarsoprol, when intended for injection.
Melphalan and its derivatives, unless listed in another Schedule.
Mephentermine.
Mepirizole.
2-mercaptopropionyl glycine.
6-mercaptopurine and its derivatives, unless listed in another Schedule.
Mercury; preparations and mixtures that contain mercury metal and that are intended for medicinal use.
Metaproterenol (orciprenaline), when intended for the prevention or delay of labour and preparations thereof for injection. (S2)
Metergoline.
Methacholine.
Methampyrone.
Methotrexate.
Methoxsalen.
Methysergide.
Metoclopramide.
Metronidazole.
Mexiletine.
Miconazole. except preparations and mixtures intended for application to the skin. (S2)
Milrinone.
Minoxidil.
Misoprostol.
Mitomycin C.
Mitoxantrone.
Mofebutazone.
Mometasone.
Morazone.
Morphazinamide.
Morphethylbutyne.
Muromonab.
Nalidixic acid.
Nalorphine.
Naloxone.
Naltrexone.
Nefopam.
Neostigmine.
Nifuratel.
Nikethamide.
Nimorazole.
Nimustine.
Niridazole.
Nitrofurantoin, except preparations thereof intended for application to the skin. (S1)
Nitrofurazone, except preparations thereof intended for application to the skin. (S1)
Nitroxoline.
Nizatidine.
Obidoxime.
Octreotide.
Olsalazine.
Omeprazole.
Ondansetron.
Ornidazole. except when intended for application to the skin. (S1)
Oxamniquine.
Oxolinic acid.
Pancuronium.
Penicillamine.
Pentamidine isethionate.
Perhexiline.
Perindopril.
Phenacetin, except preparations and mixtures intended for external use and containing not more than 0.1 per cent phenacetin as stabilizer.
Phenopyrazone.
Phenoxybenzamine.
Phenylbutazone and its derivatives, unless listed in another Schedule, except preparations intended for application to the skin. (S1)
Physostigmine, except ophthalmic preparations thereof when intended for glaucoma. (S3)
Picrotoxin.
Pilocarpine, except ophthalmic preparations thereof intended for glaucoma. (S3)
Pipemidic acid.
Pirenzepine.
Piribedil.
Piromidic acid.
Podophyllum resin; preparations and mixtures containing more than 20 per cent of podophyllum resin. (S2)
Polyglycerylene-dextran.
Pravastatin.
Praziquantel.
Procaine amide.
Procarbazine.
Propafenone.
Propylhexedrine, except when used as a vasoconstrictor and decongestant in nose preparations and inhalants. (S1)
Proteolytic (fibrinolytic) enzymes, when intended for injection. (S1)
Pyridinolcarbamate.
Pyridostigmine.
Quinapril.
Radio-active compounds, when used for diagnostic purposes.
Ramipril.
Ranitidine.
Recombinant human tissue-type plasminogen activator (rt-PA).
Rimiterol, when intended for injection. (S2)
Ritodrine.
Rosoxacin.
Roxatidine.
Salbutamol, when intended for injection. (S2)
Salmefamol, when intended for injection. (S2)
Selegiline.
Simvastatin.
Sodium aurothiomalate.
Sodium dihydroazapentacene polysulphonate.
Sodium fluoride; preparations and mixtures thereof containing 40 milligrams or more per daily dose.
Sodium nitroprusside.
Solcoseryl, except ophthalmic preparations thereof and except preparations intended for application to the skin, to the mucous membranes of the mouth and to the lips. (S1, S3)
Somatotropin.
Streptokinase.
Strychnine. except preparations and mixtures thereof. (S1, S2)
Styramate.
Sulphonamides. except those substances, preparations and mixtures intended for application to the eyes, nares and vagina. (S1)
Suramin.
Suxamethonium.
Suxethonium.
Tamoxifen.
Teniposide.
Terconazole.
Tetramisole.
Theophylline and its derivatives, unless listed in another Schedule, when intended for injection. (S1, S2)
Thiabendazole, except when intended for application to the skin. (S2)
Thioguanine.
Thymopentin.
Tibolone.
Tin fluoride, when intended for injection.
Tinidazole.
Tioconazole, except when intended for application to the skin. (S2)
Tocainide.
Toltrazuril.
Tranexamic acid.
Treosulfan.
Triethylene thiophosphoramide.
Trifluorothymidine.
Trimetaphane.
Trimethoprim.
Trioxsalen.
Triptorelin.
Tromantadine.
Tubocurarine.
Urapidil.
Urethane.
Urokinase.
Vaccines for veterinary use.
Vanillic acid diethylamide.
Vecuronium bromide.
Vidarabine.
Vinblastine.
Vincristine.
Vindesine.
Zidovudine (AZT).
Schedule 5
[Schedule 5 added by s. 36 of Act No. 65 of 1974, substituted by Government Notices No. R.420 of 7 March, 1975, No. R.2244 of 28 November, 1975, No. R.575 of 2 April, 1976 and No. R.2082 of 5 November, 1976, amended by Government Notices Nos. R. 143 of 4 February, 1977. R.279 of 25 February, 1977, R.437 of 1 April 1977, by R.1674 of 18 August, 1978 (as amended by Government Notice No. R.2410 of 8 December, 1978), No. R. 1926 of 31 August, 1979. (as amended by Government Notice No. 271 of 15 February, 1980), No. R.2416 of 12 November, 1982, No. R. 1289 of 14 June, 1985 and No. 154 of 31 January, 1986, substituted by Government Notice No. 225 of 17 February, 1989 and amended by Government Notice No. R.2841 of 7 December, 1990.]
All substances, preparations and mixtures referred to in this Schedule are excluded when registered and sold in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947).
All substances referred to in this Schedule include the following:
( a)
The salts and esters of such substances, where the existence of such salts and esters is possible; and
( b)
all preparations and mixtures of such substances, where such preparations and mixtures are not expressly excluded.
Acitretin.
Amitryptiline and its derivatives, unless listed in another Schedule.
Amoxapine.
Anaesthetic preparations containing pregnanedione derivatives.
Aponal.
Apronalide.
Azacycloool.
Barbituric acid and its derivatives, unless limed in another Schedule, excluding amobarbital, cyclobarbital, pentobarbital, and secobarbital; and except preparations and mixtures containing not more than 30 milligrams per minimum recommended or prescribed dose when intended for continued use in asthma, and not more than 90 milligrams of phenobarbitone per minimum recommended or prescribed dose when intended for continued use in epilepsy. (S1, S2, S6, S7)
Benactyzine and its derivatives, unless listed in another Schedule.
Benfluramate.
Benzoctamine.
Benzodiazepines and their derivatives, unless listed in another Schedule.
Benzquinamide.
Beta-aminopropylbenzene and beta-aminoisopropylbenzene, any compound structurally derived from either of these substances by substitution in the side chain or by ring closure therein (or by both such substitution and such ring closure) and any salt or substance falling under the above, except preparations and mixtures of the above when used as vasoconstrictors and decongestants in antihistamine nose and eye preparations and except when contained in appliances for inhalation in which the substance is absorbed in solid material and excluding d-norpseudoephedrine, ephedrine, etafedrine, N-methylephedrine, N-diethyl-aminoethylephedrine, phenylpropanolamine, prenylamine and preparations and mixtures thereof except substances listed in Schedules 8 and 9 (S1, S2).
Bromides; preparations and mixtures thereof containing 80 milligrams or more of bromine as bromide per recommended daily dose, except when specifically packaged, labelled and used for industrial and non-medicinal laboratory purposes. (S2)
Bromisovalum.
Brotizolam.
Buspirone.
Butriptyline.
Butyrophenones.
Carbromal.
Chloral derivatives, unless listed in another Schedule.
Chlormezanone, except mixtures thereof where thc maximum recommended or prescribed dose does not exceed 100 milligrams of chlormezanone. (S2)
Chlorprothixene.
Clomacran.
Clomethiazole.
Clopemthixol.
Clothiapine.
Clozapinc.
Cyclobenzaprine.
Deanol and its derivatives, unless listed in another Schedule, except when specifically packaged, labelled and used for industrial and non-medicinal laboratory purposes.
Detomidine.
Dextropropoxyphene: preparations and mixtures for oral use containing not more than 135 milligrams of dextropropoxyphene, calculated as the base, per dosage unit or with a concentration of not more than 2.5 per cent in undivided preparations. (S7)
Diprenorphine.
Dothiepin.
Doxepin.
Droperidol.
Drostanolone.
Echothiopate.
Emylcamate.
Enflurane.
Ethclorvynol.
Ethinamate and its derivatives, unless listed in another Schedule.
Etodroxizine, except preparations and mixtures thereof when used solely as an antihistaminic. (S2)
Etomidate.
Etretinate.
Fencamfamine.
Fenfluramine.
Flumazenil.
Fluoxetine.
Flupenthixol.
Fluspirilene.
Fluvoxamine.
Halothane.
Hedonal and its esters, except when specifically packaged, labelled and used for industrial and non-medicinal laboratory purposes.
Heminevrin.
Hydroxyzine.
Imipramine and its derivatives, unless listed in another Schedule.
Iproniazid.
Isoflurane.
Isotretinoin.
Ketamine.
Lithium salts, when intended for medicinal use.
Lofepramine.
Loxapine.
Maprotiline.
Mazindol.
Mechlorethamine and its derivatives, unless listed in another Schedule.
Meclofenoxate.
Melitracene.
Mephenoxalone.
Meprobamate.
Methoxyflurane.
Mianserin.
Moclobemide.
Molindone.
Nalbuphine.
Nomifensine.
Oxypertine.
Paraldehyde.
Pargyline.
Pemoline and its complexes.
Phenethylhydrazine.
Phenothiazine and its derivatives, unless listed in another Schedule, except preparations and mixtures containing promethazine or dimethothiazine or their salts when used solely as an antihistaminic, and except preparations containing promethazine or its salts when intended specifically for the treatment of travel sickness or application to the skin. (S2)
Phentermine.
Pimethixene, except preparations and mixtures thereof when used solely as an antihistaminic. (S2)
Pimozide.
Pipradol.
Pizotifen, except preparations and mixtures thereof when used solely as an antihistaminic or when intended for the prophylaxis of migraine. (S2)
Prolintane.
Propofol.
Quinupramine.
Sulphonmethane.
Sulpyride.
Tiapride.
Thiguanosine.
Thiothixene.
Tizanidine.
Tramadol.
Tranylcypromine.
Trazodone.
Trihexyphenidyl.
L-tryptophan, when intended for medicinal use, except when intended for medicinal use as supplementation for nutritional purposes. (S1)
Viloxazine.
Xylazine.
Zimelidine.
Zolazepam.
Zopiclone.
Zotepine.
Zuclopenthixol.
Schedule 6
[Schedule 6 added by s. 36 of Act No. 65 of 1974, substituted by Government Notices No. R.420 of 7 March, 1975, No. R.2244 of 28 November, 1975, No. R.575 of 2 April, 1976 and No. R.2082 of 5 November, 1976, amended by Government Notices No. R.437 of 1 April, 1977, No. R.1674 of 18 August 1978, No. R.1926 of 31 August, 1979, No. R.658 of 27 March, 1981, No. R.2416 of 12 November, 1982 and No. R.1289 of 14 June, 1985 and substituted by Government Notice No. 225 of 17 February, 1989.]
All substances referred to in this Schedule include the following:
( a)
The salts and esters of such substances, where the existence of such salts and esters is possible; and
( b)
all preparations and mixtures of such substances, where such preparations and mixtures are not expressly excluded.
Amobarbital, cyclobarbital and pentobarbital, except preparations and mixtures containing not more than 30 milligrams per minimum recommended or prescribed dose when intended for continued use in asthma, and not more than 50 milligrams per minimum recommended or prescribed dose when intended for continued use in epilepsy. (S1, S2, S5)
Buprenorphine.
Chlorphentermine.
Diethylpropion (amfepramone).
Glutethimide.
Meptazinol.
Pentazocine.
Tiletamine.
Schedule 7
[Schedule 7 added by s.36 of Act No. 65 of 1974, substituted by Government Notices No.R.420 of 7 March, 1975, No. R.2244 of 28 November, 1975, No. R.575 of 2 April, 1976 and No. R.2082 of 5 November, 1976, amended by Government Notices No. R.437 of 1 April, 1977, No. R.1567 of 12 August, 1977, No. R.1674 of 18 August, 1978 (as amended by Government Notice No. P.2410 of 8 December, 1978), No. R.1926 of 31 August, 1979, No. R.658 of 27 March, 1981, No. R.2416 of 12 November, 1982 and No. R.1289 of 14 June, 1985, substituted by Government Notice No.225 of 17 February, 1989 and amended by Government Notice No. R.2841 of 7 December, 1990.]
All substances referred to in this Schedule include the following (unless expressly excluded or unless listed in another Schedule):
( a)
The isomers of such substances, where the existence of such isomers is possible within the specific chemical designation;
( b)
the esters and ethers of such substances and of the isomers referred to in ( a), as well as the isomers of such esters and ethers, where the existence of such esters, ethers and isomers is possible;
( c)
the salts of such substances and of the isomers referred to in ( a), as well as the salts of the esters, ethers and isomers referred to in ( b), where the existence of such salts is possible;
( d)
the isomers of any of the salts referred to in ( c), where the existence of such isomers is possible;
( e)
all preparations and mixtures of any of the above.
Acetorphine.
Acetyldihydrocodeine, except preparations and mixtures containing 20 milligrams or less of acetyldihydrocodeine per recommended or prescribed dose. (S1)
Acetylmethadol.
Alfentanil.
Allylprodine.
Alphacetylmethadol.
Alphameprodine.
Alphamethadol.
Alphaprodine.
Anileridine.
Benzethidine.
Benzphetamine.
Benzylmorphine.
Betacetylmethadol.
Betameprodine.
Betamethadol.
Betaprodine.
Bezitramide.
Chlorodyne (Chloroform and Morphine Tincture BP 1980) or any preparation or mixture thereof described as chlorodyne; except preparations and mixtures containing5,0 per cent or less of chlorodyne in combination with other active medicinal substances. (S1)
Clonitazene.
Coca leaf and any salt, compound, derivative or preparation of coca leaf and any salt, compound, derivative or preparation thereof that is chemically equivalent or identical to any of these substances, whether obtained directly or indirectly by extraction from material or substances obtained from plants, or obtained independently by chemical synthesis, or by a combination of extraction and chemical synthesis, except decocainized coca leaf and extractions of coca leaf where such extractions contain no cocaine or ecgonine.
Codeine (methylmorphine), except preparations and mixtures containing 20 milligrams or less of codeine per recommended or prescribed dose. (SI )
Codoxime.
Desomorphine.
Dextromoramide.
Dextropropoxyphene, except preparations and mixtures for oral use containing 135 milligrams or less of dextropropoxyphene, calculated as the base, per dosage unit or with a concentration of not more than 2.5 per cent in undivided preparations. (S5)
Diampromide.
Diethylthiambutene.
Difenoxin (or diphenoxylic acid), except mixtures containing, per dosage unit, 0,5 milligrams or less of difenoxin, calculated as the base, and a quantity of atropine sulphate equal to at least 5,0 per cent of such quantity of difenoxin, calculated as the base, as is present in the mixture. (S2)
Dihydrocodeine, except preparations and mixtures containing 20 milligrams or less of dihydrocodeine per recommended or prescribed dose. (S1)
Dihydromorphine.
Dimenoxadol.
Dimepheptanol.
Dimethylthiambutene.
Dioxaphethyl butyrate.
Diphenoxylate, except preparations containing not more than 2,5 milligrams of diphenoxylate, calculated as the base, and not less than 25 micrograms of atropine sulphate per dosage unit. (S2)
Dipipanone.
Drotebanol.
Ecgonine, and the esters and derivatives thereof that are convertible to ecgonine and cocaine.
Ethylmethylthiambutene.
Ethylmorphine, except preparations and mixtures containing 20 milligrams or less of ethylmorphine per recommended or prescribed dose. (S1)
Etonitazene.
Etorphine.
Etoxeridine.
Fenproporex.
Fentanyl. (S8)
Furethidine.
Hydrocodone (dihydrocodeinone).
Hydromorphinol (14-hydroxydihydromorphine).
Hydromorphone (dihydromorphinone).
Hydroxypethidine.
Isomethadone.
Ketobemidone.
Levomoramide.
Levophenacylmorphan.
Levorphanol.
Mecloqualone.
Mefenorex.
Metazocine.
Methadone.
Methadone-intermediate.
Methorphan, including levomethorphan and racemethorphan, but excluding dextromethorphan. (S1)
Methyldesorphine.
Methyldihydromorphine.
Methylphenidate and its derivatives, unless listed in another Schedule.
Metopon.
Moramide-intermediate.
Morpheridine.
Morphine. except preparations and mixtures of morphine containing 0.2 per cent or less of morphine, calculated as adhydrous morphine. (S1)
Morphine methobromide and other pentavalent nitrogen morphine derivatives.
Morphine-N-oxide and its derivatives.
Myrophine (myristylbenzylmorphine).
Nicocodine.
Nicodicodine.
Nicomorphine.
Noracymethadol.
Norcodeine, except preparations and mixtures containing 20 milligrams or less of norcodeine per recommended or prescribed dose. (S1)
Norlevorphanol.
Normethadone.
Normorphine (demethylmorphine or N-demethylated morphine).
Norpipanone.
Opium and opiates and salt, compound, derivative or preparation of opium or opiates, whether obtained directly or indirectly by extraction from material or substances obtained from plants, or obtained independently by chemical synthesis, or by combination of extraction and chemical synthesis, except mixtures containing 0,2 per cent or less of morphine, calculated as anhydrous morphine. (S1)
Opium-poppy and poppy straw, whether obtained directly or indirectly by extraction from material or substances obtained from plants, or whether obtained independently by chemical synthesis, or by a combination of extraction and chemical synthesis.
Oxycodone (14-hydroxydihydrocodeinone or dihydrohydroxycodeinone).
Oxymorphone (14-hydroxydihydromorphinone or dihydrohydroxymorphinone).
Pethidine, pethidine-intermediate A, pethidine-intermediate B and pethidine-intermediate C. (S8)
Phenadoxone.
Phenampromide.
Phenazocine.
Phendimetrazine.
Phenomorphan.
Phenoperidine.
Pholcodine, except preparations and mixtures containing 20 milligrams or less of pholcodine per recommended or prescribed dose. (S1)
Piminodine.
Piritramide.
Proheptazine.
Properidine.
Propiram.
Racemoramide.
Racemorphan.
Secobarbital.
Sufentanil.
Thebacon.
Thebaine.
Tilidine.
(-)-transdelta-9-tetrahydrocannabinol, when intended for therapeutic purposes. (S8)
Trimeperidine.
Schedule 8
[Schedule 8 added by s. 36 of Act No. 65 of 1974, substituted by Government Notices No. R.420 of 7 March, 1975, No. R.2244 of 28 November, 1975, No. R.575 of 2 April, 1976 and No. R.2082 of 5 November, 1976, amended by Government Notices No.R.437 of 1 April, 1977, No. R. 1567 of 12 August, 1977, No. R.1674 of 18 August, 1978 (as amended by Government Notice No.2410 of 8 December, 1978), No. R.1926 of 31 August,
1979, No. R.658 of 27 March, 1981, No. R.2416 of 12 November, 1982 and No. R. 1289 of 14 June, 1985, substituted by Government Notice No. 225 of 17 February, 1989 and amended by Government Notices No. R. 1133 of 2 June, 1989 and No. R.2841 of 7 December, 1990.]
All substances referred to in this Schedule include the following (unless expressly excluded or unless listed in another Schedule):
( a)
The isomers of such substances, where the existence of such isomers is possible within the specific chemical designation;
( b)
the esters and ethers of such substances and of the isomers referred to in ( a), as well as the isomers of such esters and ethers, where the existence of such esters, ethers and isomers is possible;
( c)
the salts of such substances and of the isomers referred to in ( a), as well as the salts of the esters, ethers and isomers referred to in ( b), where the existence of such salts is possible;
( d)
the isomers of any of the salts referred to in ( c), where the existence of such isomers is possible;
( e)
all preparations and mixtures of any of the above.
Amphetamine. (S9)
Bufotenine (N,N-dimethylserotonin).
Cannabis (dagga), the whole plant or any portion or product thereof, except (-)-transdelta-9-tetrahydrocannabinol, when intended for therapeutic purposes. (S7)
Dexamphetamine. (S9)
Diethyltryptamine [3-(2-(diethylamino)-ethyl)-indole].
Dimethyltryptamine [3-(2-(dimethylamino)-ethyl)-indole].
Fentanyl-analogues (unless listed in another Schedule):
acetyl-alpha-methyl- fentanyl;
alpha-methyl- fentanyl;
alpha-methyl- fentanyl-acetanilide;
alpha-methyl-thio- fentanyl;
benzyl-fentanyl;
beta-hydroxy- fentanyl;
beta-hydroxy-3-methyl- fentanyl;
3-methyl-fentanyl and its two isomeric forms:
cis-N-(3-methyl-1-(2-phenethyl)-4-piperidyl) propionanilide and trans-N-(3-methyl-1-(2-phenethyl)-4-piperidyl) propionanilide;
3 methylthiofentanyl;
Para-fluoro-fentanyl; (S7)
thiofentanyl.
Harmaline (3,4-dihydroharmine).
Harmine [7-methoxy-1-methyl-9H-pyrido (3,4-b)-indole].
Heroin (diacetylmorphine).
Lysergide (Lysergic acid diethylamidemide).
Mescaline (3,4,5-trimethoxyphenethylamine).
Methamphetamine and methamphetamine racemate.
Methaqualone and any preparation containing methaqualone.
Methylenedioxyamphetamine (MDA).
N-ethyl-methylenedioxymphetamine.
N-hydroxy-methylenedioxyamphetamine.
4-methyl-2,5-dimethoxyamphetamine (DOM) and its derivatives.
4 methylaminorex.
Nabilone. (S9)
Pethidine-analogues:
1 -methyl-4-phenyl-4-propionoxy-piperidine (MPPP);
1-methyl-4-phenyl- 1,2,5,6-tetrahydropiperidine (MPTP); and
1 -phenylethyl-4-phenyl-4-acetyloxy-piperidine (PEPAP).
Phencyclidine and its congeners N-ethyl- 1 -phenylcyclohexylamine (PCE), 1 -(1 -phenylcyclohexyl) pyrrolidine (PHP or PCPY) and 1-[1-(2-thienyl) cyclohexyl] pipendine (TCP).
Phenmetrazine.
Psilocin (4-hydroxydimethyltryptamine).
Psylocybin (4-phosphoryloxy-N, N-dimethyltryamine).
Tetrahydrocannabinol.
Schedule 9
[Schedule 9 added by s. 36 of Act No. 65 of 1974, substituted by Government Notices No. R.420 of 7 March, 1975, No. R.2244 of 28 November, 1975, No. R.575 of 2 April, 1976 and No. R.2082 of 5 November, 1976, amended by Government Notices No. R.437 of 1 April, 1977, No. R.2416 of 12 November, 1982 and No. R. 1289 of 14 June, 1985 and substituted by Government Notice No. 225 of 17 February, 1989.]
Amphetamine and its salts; preparations thereof. (S8)
Dexamphetamine and its salts; preparations thereof. (S8)
Nabilone.